Premium
Less severe retinopathy of prematurity induced by surfactant replacement therapy
Author(s) -
Termote J,
SchalijDelfos NE,
Cats BP,
WittebolPost D,
Hoogervorst BR,
Brouwers HAA
Publication year - 1996
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1996.tb13958.x
Subject(s) - retinopathy of prematurity , medicine , odds ratio , confidence interval , surfactant therapy , case control study , pediatrics , gestational age , pregnancy , genetics , biology
To assess the effect of surfactant replacement therapy (SRT) on the prevalence and severity of retinopathy of prematurity (ROP), we compared data from 160 SRT‐treated preterm infants with data from 230 historic controls. The prevalence of ROP was 30.6% in the treatment group and 23.4% in the control group. Severe ROP (stages 3‐4) was seen in 6.1% of the infants with ROP in the treatment group and 20.3% of the ROP patients in the control group. Surfactant therapy had no influence on the prevalence of ROP (odds ratio 1.4, 95% confidence interval 0.797‐2.459, p = 0.242). However, SRT was associated with a decreased risk for severe ROP, compared to mild ROP (odds ratio 0.226, 95% confidence interval 0.056‐0.905, p = 0.036). These data suggest that SRT is associated with a decreased risk for severe ROP.